E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 8/29/2006 in the Prospect News Biotech Daily and Prospect News Convertibles Daily.

Fitch: Schering-Plough unaffected

Fitch Ratings said it does not anticipate a change to Schering-Plough Corp.'s ratings following the settlement reached with the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts regarding the investigation into the company's sales, marketing and clinical trial practices.

The agreement, which resolves the investigation, includes a total settlement amount of $435 million including $180 million of criminal fines and $255 million for civil issues. The settlement amount is still subject to court approval. Additionally, an addendum will be added to Schering-Plough's existing corporate integrity agreement with the Office of Inspector General.

Fitch said that the aggregate payment was both within the company's litigation reserve and the agency's expectations and that the agency looks favorably on continued actions of current executive management to reduce litigation exposure inherited from the previous management team.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.